Synaptogenix Total Assets 2020-2025 | TAOX
Synaptogenix total assets from 2020 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
Synaptogenix Annual Total Assets
(Millions of US $) |
| 2024 |
$18 |
| 2023 |
$31 |
| 2022 |
$39 |
| 2021 |
$36 |
| 2020 |
$7 |
| 2019 |
$18 |
Synaptogenix Quarterly Total Assets
(Millions of US $) |
| 2025-03-31 |
$15 |
| 2024-12-31 |
$18 |
| 2024-09-30 |
$23 |
| 2024-06-30 |
$28 |
| 2024-03-31 |
$29 |
| 2023-12-31 |
$31 |
| 2023-09-30 |
$32 |
| 2023-06-30 |
$33 |
| 2023-03-31 |
$37 |
| 2022-12-31 |
$39 |
| 2022-09-30 |
$27 |
| 2022-06-30 |
$30 |
| 2022-03-31 |
$32 |
| 2021-12-31 |
$36 |
| 2021-09-30 |
$32 |
| 2021-06-30 |
$33 |
| 2021-03-31 |
$0 |
| 2020-12-31 |
$0 |
| 2020-09-30 |
$0 |
| 2020-06-30 |
$0 |
| 2019-12-31 |
$18 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.012B |
$0.000B |
|
Synaptogenix Inc. is an emerging biopharmaceutical company. It focused on developing therapies for neurodegenerative diseases. The company's lead therapeutic candidate consist Bryostatin-1. Synaptogenix Inc. is based in NEW YORK.
|
